Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction

Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions

(2012) Dylan T Jones et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Homodimerization of the PAS-B Domains of Hypoxia-Inducible Factors

(2012) Jing Zhu et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

(2012) Gregg L. Semenza   TRENDS IN PHARMACOLOGICAL SCIENCES

Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels

(2012) Hiroshi Harada et al.   Nature Communications

Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development

(2011) Ralf Buettner et al.   ACS Chemical Biology

Data processing and analysis with theautoPROCtoolbox

(2011) Clemens Vonrhein et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

The benefits of constructing leads from fragment hits

(2011) N Foloppe   Future Medicinal Chemistry

Design and Synthesis of Novel Small-Molecule Inhibitors of the Hypoxia Inducible Factor Pathway

(2011) Suazette Reid Mooring et al.   JOURNAL OF MEDICINAL CHEMISTRY

The resurgence of covalent drugs

(2011) Juswinder Singh et al.   NATURE REVIEWS DRUG DISCOVERY

A Structure-Guided Approach to Creating Covalent FGFR Inhibitors

(2010) Wenjun Zhou et al.   CHEMISTRY & BIOLOGY

Strategies for discovering and derisking covalent, irreversible enzyme inhibitors

(2010) Douglas S Johnson et al.   Future Medicinal Chemistry

Quantitative reactivity profiling predicts functional cysteines in proteomes

(2010) Eranthie Weerapana et al.   NATURE

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The VHL Tumor Suppressor: Master Regulator of HIF

(2009) Volker Haase   CURRENT PHARMACEUTICAL DESIGN

Principles of Ligand Binding within a Completely Buried Cavity in HIF2α PAS-B

(2009) Jason Key et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

Artificial ligand binding within the HIF2  PAS-B domain of the HIF2 transcription factor

(2009) T. H. Scheuermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapid degradation of hypoxia-inducible factor-1α by KRH102053, a new activator of prolyl hydroxylase 2

(2008) H J Choi et al.   BRITISH JOURNAL OF PHARMACOLOGY

PX-478, an inhibitor of hypoxia-inducible factor-1α, enhances radiosensitivity of prostate carcinoma cells

(2008) Sanjeewani T. Palayoor et al.   INTERNATIONAL JOURNAL OF CANCER

Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping

(2008) Steven W. Muchmore et al.   Journal of Chemical Information and Modeling

A RNA antagonist of hypoxia-inducible factor-1 , EZN-2968, inhibits tumor cell growth

(2008) L. M. Greenberger et al.   MOLECULAR CANCER THERAPEUTICS

Fragment-Based Approach to Drug??Lead Discovery

(2008) Daniela Fattori et al.   Drugs in research & development